BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34713369)

  • 1. Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
    Kepenekian V; Péron J; You B; Bonnefoy I; Villeneuve L; Alyami M; Bakrin N; Rousset P; Benzerdjeb N; Glehen O
    Ann Surg Oncol; 2022 Mar; 29(3):2104-2113. PubMed ID: 34713369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
    Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
    Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
    Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
    Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
    Giger-Pabst U; Demtröder C; Falkenstein TA; Ouaissi M; Götze TO; Rezniczek GA; Tempfer CB
    BMC Cancer; 2018 Apr; 18(1):442. PubMed ID: 29669524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
    Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
    Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
    Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
    Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 14. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Girshally R; Demtröder C; Albayrak N; Zieren J; Tempfer C; Reymond MA
    World J Surg Oncol; 2016 Sep; 14(1):253. PubMed ID: 27678344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
    Klos D; Hanuliak J; Lemstrova R; Mohelnikova-Duchonova B; Zapletalova J; Melichar B; Risko J
    Bratisl Lek Listy; 2023; 124(5):345-350. PubMed ID: 36876363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
    Wang X; Katz S; Miura J; Karakousis G; Roshkovan L; Walker S; McNulty S; Ciunci C; Cengel K; Langer CJ; Marmarelis ME
    PLoS One; 2022; 17(9):e0275187. PubMed ID: 36174024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer.
    Alyami M; Bonnot PE; Mercier F; Laplace N; Villeneuve L; Passot G; Bakrin N; Kepenekian V; Glehen O
    Eur J Surg Oncol; 2021 Jan; 47(1):123-127. PubMed ID: 32561204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.